Clinicopathologic characteristics, therapeutic modalities and survival outcomes of plasmablastic lymphoma: A real-world study

Introduction Plasmablastic lymphoma(PBL)，an extremely rare subtype of B-cell non-Hodgkin lymphoma, is characterized by aggressiveness, rapid progression and bleak prognosis. Neither standardized regimen nor consensus for PBL treatment has been established. Material methods We retrospectively analyzed the clinicopathologic characteristics, therapeutic modalities survival outcomes 418 patients registered in Surveillance, Epidemiology, End Results (SEER) database from 2008 to 2016 21 (19 treated) our institution. Kaplan-Meier curves log-rank test overall disease-specific were performed compare each variable. Variables with statistical significance univariate Cox regression incorporated into multivariate model determine independent prognostic factors. In patient cohort SEER, a striking male predilection. The median OS all was 17 months. 1-year,3-year 5-year rate 54.4%, 40.4% 37.2% respectively.Chemotherapy alone or chemotherapy combined radiotherapy could significantly reduce risk death extend patients’ survival, yielding HR 0.209(95%CI 0.152-0.288) 0.187(95%CI 0.089-0.394), respectively. Radiation seemed useless. All institution HIV-negative. main regimens CHOP CHOPE, DA-EPOCH, DHAP ESHAP. Complete response achieved only 3 patients, while partial 10 patients. 7 Fourteen later died disease progression. Conclusions Previous malignancy history, Ann Arbor stage modality Bortezomib DA-EPOCH may serve as an effective PBL. optimal necessitates further exploration.